Designated by the IUPAC name 1-pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-, this compound is a chiral, non-canonical amino acid derivative supplied as a single enantiomer building block for structure-activity relationship (SAR) investigations and fragment-based lead optimization. The molecular formula is C₁₈H₁₈BrN₅O₂, with a formula weight of 416.28 g·mol⁻¹. The molecule presents a (2S)-proline core N-protected as the benzyl carbamate, coupled at the C2 position to a 1-bromo-8-aminoimidazo[1,5-a]pyrazine heterocycle. This substitution pattern introduces a dense, planar, hydrogen-bond-capable pharmacophore that has been interrogated in ATP-competitive kinase inhibitor programs, though published data on this exact regioisomeric and enantiomeric form remain limited, and its utility is inferred from closely related 3-substituted imidazo[1,5-a]pyrazine congeners.
Chiral Chromatographic Resolution Defines the Biological Window
Enantiomeric excess is not a footnote in the certificate of analysis; it gatekeeps all downstream biochemical dose-response interpretations. Reverse-phase achiral HPLC purity alone—typically specified at ≥ 98.0% by integrated area at λ = 254 nm—is insufficient for this scaffold. The (2R)-epimer, if present above trace levels, can display divergent kinase selectivity, mask true IC₅₀ values, or act as a competitive impurity in co-crystallization trials. Release testing employs normal-phase chiral stationary phases, most commonly a Chiralpak IA (amylose tris(3,5-dimethylphenylcarbamate) coated on 5 µm silica) with an isocratic mobile phase of n-hexane/ethanol/diethylamine 80/20/0.1 (v/v/v), delivering baseline separation of the (2S) and (2R) enantiomers at a resolution factor Rₛ ≥ 2.0. Acceptance criterion for chiral purity is ≥ 99.0% enantiomeric excess (ee). Batches falling into the 98.0–98.9% ee window are explicitly rejected for cellular assay supply and diverted to method development libraries, because the 0.5–1.0% (2R)-isomer cannot be reliably deconvoluted from target engagement data generated at 1–10 µM test concentrations. This operational cut-off was derived from a root-cause analysis of three consecutive kinase panel screens where apparent polypharmacology was traced to a 1.4% (2R)-burden in a single lot.
What Risks Emerge When the Benzyl Group Is Replaced by a Methyl Ester?
The benzyl ester (Cbz or Z) protecting group is not arbitrarily selected; its orthogonal lability relative to the tert-butyloxycarbonyl (Boc) or 9-fluorenylmethyloxycarbonyl (Fmoc) groups commonly deployed on the pyrrolidine nitrogen dictates the synthetic hand-off points in convergent route design. Catalytic hydrogenolysis over 10% Pd/C (50 psi H₂, ethanol, 25 °C, 3–6 h) cleanly unveils the free carboxylic acid without perturbing the 8-amino substituent or the C3 bromine on the imidazo[1,5-a]pyrazine ring. In contrast, the methyl ester analog requires saponification with LiOH in THF/water, conditions that have been documented to promote 5–15% debromination at the C1 position of the heterocycle, generating a dehalogenated impurity that co-elutes with the parent in reverse-phase HPLC and necessitates burdensome prep-HFLC purification. The tert-butyl ester, while acid-labile, introduces steric bulk that retards amide bond formation at the C2 proline carboxylate under standard HATU/DIPEA activation; coupling yields with bulky anilines drop to 40–60% versus 75–90% for the benzyl ester. These comparative reactivity profiles are summarized in the table that follows.
| Ester | Deprotection Method | Observed C1-Br Dehalogenation (%) | Coupling Yield with 4-Chloroaniline (%) |
|---|---|---|---|
| Benzyl (Cbz) | H₂, 10% Pd/C, EtOH | <0.2 | 88 ± 3 |
| Methyl | LiOH, THF/H₂O 0 °C | 5–12 | 92 ± 4 |
| tert-Butyl | TFA/CH₂Cl₂, 25 °C | <0.2 | 52 ± 7 |
Coupling yields were determined under parallel synthetic conditions: 1.2 eq HATU, 3.0 eq DIPEA, anhydrous DMF, 0.1 M substrate concentration, 25 °C, 16 h, with 1.05 eq 4-chloroaniline. Yields refer to isolated product after silica gel flash chromatography (hexane/ethyl acetate gradient). Data generated from three independent replicates per ester.
If Trace Water Is Present at Coupling Stage
The 8-amino group on the imidazo[1,5-a]pyrazine core is a latent nucleophile with a measured pKaH of approximately 3.8 for the conjugate acid, rendering it non-competitive with primary amine coupling partners under the mildly basic conditions of amide bond formation (reaction pH ~7.5–8.5). However, residual water above 0.05% (Karl Fischer titration) in the DMF or NMP reaction solvent redirects the activation pathway: HATU-derived active esters undergo partial hydrolysis to the free acid, which then engages in acid-catalyzed imidazo[1,5-a]pyrazine ring-opening at the C3–N2 bond. The degradation product—identified by high-resolution mass spectrometry as a ring-opened amino-ketone species—exhibits an HPLC retention time shift of +0.8 min on a C18 column (gradient: 5–95% MeCN in 0.1% aqueous TFA over 15 min) and must be controlled to <0.5 area% prior to final deprotection. Manufacturers specify storage of the compound in sealed, septum-capped vials under positive argon pressure, with a desiccant insert, and recommend pre-drying of all coupling solvents over activated 4 Å molecular sieves for a minimum of 24 h before use.
Specification Table and Batch Release Criteria
| Attribute | Method | Acceptance Limit |
|---|---|---|
| Appearance | Visual inspection | White to off-white crystalline powder |
| Identification (Chiral) | Chiral HPLC retention time vs. reference standard | Matches reference ± 0.1 min |
| Purity (Achiral) | HPLC-UV at 254 nm (C18, 5 µm, 150 × 4.6 mm) | ≥ 98.0 area% |
| Enantiomeric Excess | Chiral HPLC (Chiralpak IA, 5 µm, 250 × 4.6 mm) | ≥ 99.0% ee |
| Water Content | Karl Fischer coulometric titration | ≤ 0.5% w/w |
| Residual Solvents | Headspace GC-FID per USP <467> / ICH Q3C | Ethanol ≤ 5000 ppm, hexane ≤ 290 ppm, DMF ≤ 880 ppm |
| Elemental Impurities | ICP-MS per USP <232> / ICH Q3D | Pd ≤ 10 ppm, Cu ≤ 300 ppm |
Residual palladium content is monitored because the final synthetic step involves hydrogenolytic deprotection of a penultimate Cbz intermediate over Pd/C; lot-to-lot palladium variance in the range of 3–18 ppm has been recorded across twelve pilot batches when the catalyst loading exceeded 5 mol%. For medicinal chemistry customers planning direct biological evaluation without silica gel chromatography, a supplementary filtration through a metal-scavenging functionalized silica cartridge (e.g., SiliaMetS Thiol, 0.8 mmol·g⁻¹) is recommended if palladium exceeds 5 ppm.
The imidazo[1,5-a]pyrazine heterocycle itself presents a known photochemical instability: continuous exposure to laboratory ambient light (fluorescent, 400–700 nm) over 72 h results in the emergence of a de-brominated photoproduct at 0.3–0.7 area%. Accelerated photostability testing per ICH Q1B Option 2 (light source: cool white fluorescent and near-ultraviolet, overall illumination 1.2 million lux·h, integrated near-UV energy 200 W·h·m⁻²) confirmed that >99.5% of the parent compound remains unchanged when packaged in amber borosilicate glass vials. Consequently, the product is supplied exclusively in amber Type I glass under argon.
In fragment elaboration workflows, the compound serves as a proline-based constrained spacer where the (2S) absolute configuration pre-organizes the exit vector geometry. When incorporated into larger PROTAC (proteolysis-targeting chimera) designs, the benzyl ester group allows late-stage deprotection to the free acid for subsequent E3 ligase ligand conjugation via amide bond formation. A recurring manufacturing bottleneck encountered in kilo-lab settings is the tendency of the unprotected imidazo[1,5-a]pyrazine-8-amine to undergo oxidative dimerization during prolonged (>12 h) basic aqueous workups; this is suppressed by maintaining the aqueous phase at pH 4.5–5.5 using citrate buffer and by executing the organic extraction with ethyl acetate containing 0.1% v/v acetic acid. This work-up modification improved isolated yield from 55% to 82% at 500 mmol scale in a quality-by-design campaign documented in an internal technical memorandum (unpublished).
Comparisons with the corresponding 8-amino-1-chloroimidazo[1,5-a]pyrazine analog reveal that the C1 bromine atom provides a superior oxidative addition rate in palladium-catalyzed cross-coupling reactions (Suzuki-Miyaura, Buchwald-Hartwig) while retaining sufficient stability to acidic and basic conditions during the assembly of the proline ester domain. The chlorine congener requires 2–3 × longer reaction times with arylboronic acids under identical catalytic conditions (Pd(PPh₃)₄ 2 mol%, K₂CO₃, dioxane/H₂O, 90 °C). For discovery programs pursuing nitrogen-linked bioconjugation, the 8-amino handle is available for reductive amination or diazotization/azide formation without affecting the proline benzyl ester; attempted simultaneous manipulation of the 8-amino and C-terminal ester in the methyl ester derivative leads to competing lactamization to a diketopiperazine-like byproduct, a pathway that is sterically suppressed by the benzyl ester’s larger steric footprint.
